Viking Therapeutics rises on plans to test oral obesity drug in late-stage studies

Shares of obesity drug developer Viking Therapeutics VKTX.O rise 9.4% to $31.24 after hours

VKTX says it plans to advance its experimental oral obesity drug VK2735 into late-stage trials in Q3 of this year

"The company believes the availability of both an oral and an injectable formulation is an important factor differentiating VK2735 from competitive agents, as no other dual or triple agonist is currently available in both formulations" — VKTX

Late-stage study results have shown that once-daily doses of the oral tablet formulation of VK2735 showed up to 12.2% average weight loss after 13 weeks

VKTX was down 12.6% in 2025